Evaluation of the anticholinergic actions of glycopyrronium bromide.
1. Glycopyrronium was evaluated by intramuscular, intravenous and oral routes in six adult volunteers for its efficacy as an antisialogogue as also for its action on other aspects of cholinergic activity. 2. It was found to be an effective antisialogogue of long duration of action by all three routes. When given orally the effects were delayed in onset and persisted for too long. Intramuscular and intravenous routes were useful. The intramuscular absorption of the drug is rapid and consistent. 3. Sweat gland activity was affected in a similar fashion but less consistently and other parameters were mostly unaffected. 4. Glycopyrronium 0.2 mg intramuscularly was found to be the optimal dose. Larger doses produced subjective discomfort out of proportion to a further reduction in salivary secretion. 5. Intravenous administration causes no changes in cardiovascular stability.
D000284:Administration, Oral; D000328:Adult; D004305:Dose-Response Relationship, Drug; D006024:Glycopyrrolate / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D010276:Parasympatholytics; D011759:Pyrrolidines / Q000494:pharmacology*; D012472:Salivation / Q000187:drug effects; D013545:Sweat Glands / Q000187:drug effects; D013997:Time Factors
D010276:Parasympatholytics; D011759:Pyrrolidines; D006024:Glycopyrrolate